logo-loader
viewImugene Ltd

Imugene receives independent confirmation of HER-Vaxx safety

The Independent Data Monitoring Committee’s role is to review study data and conduct a formal independent review of key data such as deaths, adverse reactions and laboratory results.

Imugene Ltd - Imugene receives IDMC confirmation of HER-Vaxx study safety
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies

Imugene Limited (ASX:IMU) (OTCMKTS:IUGNF) has received confirmation from the Independent Data Monitoring Committee (IDMC) of the safety and importance of the HER-Vaxx cancer immunotherapy.

The IDMC’s role is to review study data and conduct a formal independent review of key data such as deaths, adverse reactions and laboratory results, enabling the IDMC to clearly weigh the benefits and risks of continued study participation.

As a result of the review, the IDMC chair confirmed the IDMC members had no safety concerns and that the study should continue without modification.

The IDMC has encouraged Imugene to push ahead with this important study.

“Significant milestone”

Imugene managing director and CEO Leslie Chong said: “I am happy to report that we have achieved this significant milestone and I’m highly encouraged by the positive outcome of this first IDMC meeting.

“I am truly pleased with the study progress to date.”

Imugene’s HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.

It has been shown in pre-clinical studies and in Phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Benefit of IDMC review

The IDMC ensures the interests of patients entered on the trial are being well-served (ie, that the risk-benefit ratio is appropriate) and that the scientific integrity of the trial is maintained between trial initiation and completion.

A key benefit of IDMC review of trial data is an independent assessment to assure that study participants are not exposed to unnecessary or unreasonable risks because of their trial participation.

The IDMC is a key process by which the highest scientific and ethical standards are maintained in a clinical trial.

It conducts business in “closed sessions” with meetings attended only by members of the IDMC, thereby maintaining independence from the sponsor.

IDMC’s analyse ongoing data for randomised studies, including those that involve multiple sites and when statistically required per protocol, analyse important clinical endpoints such as survival or disease progression.

Phase-2 HER-Vaxx study

The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein.

This study is randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of-care chemotherapy alone.  

The primary endpoint is overall survival and secondary endpoint will be progression-free survival.

Safety, tolerability and immune response will also be measured.

The Phase 2 trial is being conducted at multiple sites across Eastern Europe and India where clinicians have difficulty accessing approved antibody treatments such as Herceptinâ and Perjetaâ marketed by Swiss multinational Roche Holding AG.

There is also a high prevalence of gastric cancer in the countries selected.

Quick facts: Imugene Ltd

Price: 0.057 AUD

ASX:IMU
Market: ASX
Market Cap: $252.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

2 weeks, 4 days ago

3 min read